Market Price

52.66 

0.45 0.9%

as of Dec 11 '19

52 Week Range:

37.48 52.98


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Hologic, Inc., a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health. The company offers Aptima molecular diagnostic assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assay technologies, instrumentation, Invader chemistry platform, ThinPrep system, and rapid fetal fibronectin test products. It also provides breast imaging and analytics products, such as 2D and 3D mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, and breast biopsy and biopsy site markers, as well as localization, specimen radiology, ultrasound, and connectivity solutions. In addition, the company offers Selenia Dimensions and 3Dimensions gantries for performing 2D and tomosynthesis image acquisition and display; C-View and Intelligent 2D software products; SecurView Workstations; computer aided detection systems; and stereotactic breast biopsy systems. Further, it provides SculpSure, PicoSure, and MonaLisa Touch aesthetic treatment systems; TempSure, a radio frequency energy sourced platform; and MedLite and other products, and system components for medical aesthetics. Additionally, the company offers NovaSure, an endometrial ablation system to treat women suffering from abnormal uterine bleeding; MyoSure surgical products for removal of fibroids, and uterine polyps and other pathology; and Horizon DXA System and Fluoroscan Insight FD skeletal health products. It sells its products through direct sales and service forces, and a network of independent distributors and sales representatives. The company was founded in 1985 and is headquartered in Marlborough, Massachusetts.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Sep '09 Sep '10 Sep '11 Sep '12 Sep '13 Sep '14 Sep '15 Sep '16 Jul '17 Sep '18 Sep '19
Equity (BVPS) 9.75
10.41
11.20
11.32
11.02
7.31
7.92
7.36
10.41
9.07
8.28
growth rate 6.8% 7.6% 1.1% -2.7% -33.7% 8.3% -7.1% 41.4% -12.9% -8.7%
Earnings BIT -2,090.00
-54.99
227.39
-61.66
-1,190.00
365.10
483.60
571.30
565.10
543.90
581.50
growth rate 0.0% 100.0% -100.0% 0.0% 100.0% 32.5% 18.1% -1.1% -3.8% 6.9%
Avg.PE -1.60
-64.50
25.58
-67.10
-3.22
441.83
88.91
31.67
15.22
10.28
10.28
growth rate 0.0% 100.0% -100.0% 0.0% 100.0% -79.9% -64.4% -51.9% -32.5% 0.0%
ROA -31.48
-1.11
2.70
-0.89
-12.04
0.20
1.64
4.41
9.88
-1.46
-2.98
growth rate 0.0% 100.0% -100.0% 0.0% 100.0% 720.0% 168.9% 124.0% -100.0% 0.0%
ROE -60.83
-2.41
5.58
-2.50
-47.85
0.86
6.35
15.67
30.67
-4.27
-8.96
growth rate 0.0% 100.0% -100.0% 0.0% 100.0% 638.4% 146.8% 95.7% -100.0% 0.0%
ROIC -37.49
1.05
5.38
0.60
-13.44
2.44
4.22
7.56
14.55
-0.12
-1.90
growth rate 100.0% 412.4% -88.9% -100.0% 100.0% 73.0% 79.2% 92.5% -100.0% 0.0%
Cur. Ratio 2.49
2.49
2.64
2.36
1.49
2.53
1.34
1.47
0.79
1.23
1.68
growth rate 0.0% 6.0% -10.6% -36.9% 69.8% -47.0% 9.7% -46.3% 55.7% 36.6%
Quick Ratio 1.69
1.81
2.02
1.47
1.13
1.83
0.96
1.10
0.58
0.89
1.17
growth rate 7.1% 11.6% -27.2% -23.1% 62.0% -47.5% 14.6% -47.3% 53.5% 31.5%
Leverage 2.26
2.08
2.04
3.54
4.64
4.08
3.69
3.41
2.87
2.98
3.04
growth rate -8.0% -1.9% 73.5% 31.1% -12.1% -9.6% -7.6% -15.8% 3.8% 2.0%
Balance Sheet Sep '09 Sep '10 Sep '11 Sep '12 Sep '13 Sep '14 Sep '15 Sep '16 Jul '17 Sep '18 Sep '19
Acct.Receivable 263.20
283.10
358.32
421.05
409.30
396.00
416.10
447.00
533.50
579.20
648.70
growth rate 7.6% 26.6% 17.5% -2.8% -3.3% 5.1% 7.4% 19.4% 8.6% 12.0%
Acct.Payable 388.79
459.60
392.30
92.10
117.00
156.90
166.60
192.20
186.50
growth rate 18.2% -14.6% -76.5% 27.0% 34.1% 6.2% 15.4% -3.0%
Cur.Assets 818.60
1,098.90
1,342.90
1,563.01
1,624.20
1,565.80
1,265.80
1,326.60
1,478.60
1,723.20
1,793.10
growth rate 34.2% 22.2% 16.4% 3.9% -3.6% -19.2% 4.8% 11.5% 16.5% 4.1%
Total Assets 5,684.20
5,625.80
6,008.78
10,477.11
9,000.80
8,414.70
7,642.50
7,317.00
7,979.60
7,230.90
6,442.10
growth rate -1.0% 6.8% 74.4% -14.1% -6.5% -9.2% -4.3% 9.1% -9.4% -10.9%
Cash 293.20
515.60
712.87
566.13
829.40
736.10
491.30
548.40
540.60
666.70
601.80
growth rate 75.9% 38.3% -20.6% 46.5% -11.3% -33.3% 11.6% -1.4% 23.3% -9.7%
Inventory 179.90
192.50
230.54
367.19
289.40
330.60
283.10
274.70
331.60
384.10
444.90
growth rate 7.0% 19.8% 59.3% -21.2% 14.2% -14.4% -3.0% 20.7% 15.8% 15.8%
Cur.Liabilities 329.30
441.90
509.45
661.35
1,088.40
619.60
943.40
901.90
1,865.50
1,402.60
1,070.10
growth rate 34.2% 15.3% 29.8% 64.6% -43.1% 52.3% -4.4% 106.8% -24.8% -23.7%
Liabilities 2,958.20
2,927.30
3,071.89
7,516.08
7,059.30
6,351.70
5,563.30
5,174.30
5,194.90
4,802.10
4,326.40
growth rate -1.0% 4.9% 144.7% -6.1% -10.0% -12.4% -7.0% 0.4% -7.6% -9.9%
LT Debt 1,513.90
1,447.10
1,488.58
4,971.18
4,242.10
4,153.20
3,221.00
3,049.40
2,172.10
2,704.60
2,783.60
growth rate -4.4% 2.9% 234.0% -14.7% -2.1% -22.5% -5.3% -28.8% 24.5% 2.9%
Equity 2,726.00
2,698.50
2,936.90
2,961.03
1,941.50
2,063.00
2,079.20
2,142.70
2,784.70
2,428.80
2,115.70
growth rate -1.0% 8.8% 0.8% -34.4% 6.3% 0.8% 3.1% 30.0% -12.8% -12.9%
Common Shares 257.00
259.00
264.00
264.00
269.00
278.00
290.00
286.00
286.00
275.00
269.00
growth rate 0.8% 1.9% 0.0% 1.9% 3.4% 4.3% -1.4% 0.0% -3.9% -2.2%
Cash Flow Statement Sep '09 Sep '10 Sep '11 Sep '12 Sep '13 Sep '14 Sep '15 Sep '16 Jul '17 Sep '18 Sep '19
Capital Expenditures 58.20
46.70
55.66
78.70
90.10
80.20
89.40
94.50
107.60
105.60
109.10
growth rate -19.8% 19.2% 41.4% 14.5% -11.0% 11.5% 5.7% 13.9% -1.9% 3.3%
Cash Dividends 0.00
2.70
0.00
0.00
0.00
growth rate -100.0%
Cash From OA 550.50
456.70
456.02
370.20
493.80
508.40
796.80
798.20
8.30
732.90
649.50
growth rate -17.0% -0.2% -18.8% 33.4% 3.0% 56.7% 0.2% -99.0% 8,730.1% -11.4%
FCF per Share 1.87
1.56
1.48
1.27
1.49
1.39
2.10
2.40
-0.16
2.01
1.92
growth rate -16.6% -5.1% -14.2% 17.3% -6.7% 51.1% 14.3% -100.0% 100.0% -4.5%
Sale Purchase of Stock 15.01
28.60
75.10
81.40
70.00
38.50
49.00
growth rate 90.6% 162.6% 8.4% -14.0% -45.0% 27.3%
FCF 481.00
404.00
392.00
287.00
404.00
428.00
697.00
689.00
-99.00
627.00
535.00
growth rate -16.0% -3.0% -26.8% 40.8% 5.9% 62.9% -1.2% -100.0% 100.0% -14.7%
Income Statement Sep '09 Sep '10 Sep '11 Sep '12 Sep '13 Sep '14 Sep '15 Sep '16 Jul '17 Sep '18 Sep '19
Sales 1,637.10
1,679.60
1,789.35
2,002.60
2,492.30
2,530.70
2,705.00
2,832.70
3,058.80
3,217.90
3,367.30
growth rate 2.6% 6.5% 11.9% 24.5% 1.5% 6.9% 4.7% 8.0% 5.2% 4.6%
Op.Income -2,016.70
69.90
127.26
-115.90
-1,182.00
365.10
483.60
571.30
565.10
543.90
581.50
growth rate 100.0% 82.1% -100.0% 0.0% 100.0% 32.5% 18.1% -1.1% -3.8% 6.9%
IBT -2,154.10
-55.00
227.39
-61.70
-1,192.90
48.10
177.20
415.30
1,230.50
-418.60
-257.70
growth rate 0.0% 100.0% -100.0% 0.0% 100.0% 268.4% 134.4% 196.3% -100.0% 0.0%
Net Income -2,216.60
-62.80
127.26
-115.90
-1,182.00
17.30
131.60
330.80
755.50
-111.30
-203.60
growth rate 0.0% 100.0% -100.0% 0.0% 100.0% 660.7% 151.4% 128.4% -100.0% 0.0%
EPS -8.64
-0.24
0.59
-0.28
-4.36
0.06
0.45
1.16
2.64
-0.40
-0.76
growth rate 0.0% 100.0% -100.0% 0.0% 100.0% 650.0% 157.8% 127.6% -100.0% 0.0%
Gross Profit 857.50
736.60
923.18
994.40
1,161.40
1,587.00
1,732.40
1,856.70
1,957.40
2,017.20
2,075.20
growth rate -14.1% 25.3% 7.7% 16.8% 36.7% 9.2% 7.2% 5.4% 3.1% 2.9%
R&D 102.50
104.30
116.70
131.00
197.60
203.20
214.90
232.10
232.80
218.70
232.20
growth rate 1.8% 11.9% 12.3% 50.8% 2.8% 5.8% 8.0% 0.3% -6.1% 6.2%

Quarterly Statements

Item Name Sep '18 Dec '18 Mar '19 Jun '19 Sep '19
Earnings BIT 137.70
144.00
134.50
149.80
153.10
growth rate 4.6% -6.6% 11.4% 2.2%
Balance Sheet Sep '18 Dec '18 Mar '19 Jun '19 Sep '19
Acct.Receivable 579.20
578.60
557.50
586.80
648.70
growth rate -0.1% -3.7% 5.3% 10.6%
Acct.Payable 192.20
176.30
165.20
161.50
186.50
growth rate -8.3% -6.3% -2.2% 15.5%
Cur.Assets 1,723.20
1,401.90
1,511.00
1,591.80
1,793.10
growth rate -18.7% 7.8% 5.4% 12.7%
Total Assets 7,230.90
6,931.50
6,525.30
6,522.40
6,442.10
growth rate -4.1% -5.9% 0.0% -1.2%
Cash 666.70
311.10
401.00
427.90
601.80
growth rate -53.3% 28.9% 6.7% 40.6%
Inventory 384.10
418.60
443.40
467.90
444.90
growth rate 9.0% 5.9% 5.5% -4.9%
Cur.Liabilities 1,402.60
1,077.70
1,045.20
1,015.20
1,070.10
growth rate -23.2% -3.0% -2.9% 5.4%
Liabilities 4,802.10
4,537.10
4,365.50
4,305.90
4,326.40
growth rate -5.5% -3.8% -1.4% 0.5%
LT Debt 2,704.60
2,807.90
2,799.70
2,791.60
2,783.60
growth rate 3.8% -0.3% -0.3% -0.3%
Equity 2,428.80
2,394.40
2,159.80
2,216.50
2,115.70
growth rate -1.4% -9.8% 2.6% -4.6%
Common Shares 2.90
2.90
2.90
2.90
2.90
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Sep '18 Dec '18 Mar '19 Jun '19 Sep '19
Capital Expenditures 32.10
22.60
29.30
25.80
31.40
growth rate -29.6% 29.7% -12.0% 21.7%
Cash Dividends
growth rate
Cash From OA 232.40
104.60
133.50
163.70
247.70
growth rate -55.0% 27.6% 22.6% 51.3%
Sale Purchase of Stock
growth rate
FCF 200.30
82.00
104.20
137.90
216.30
growth rate -59.1% 27.1% 32.3% 56.9%
Income Statement Sep '18 Dec '18 Mar '19 Jun '19 Sep '19
Sales 813.40
830.70
818.40
852.40
865.90
growth rate 2.1% -1.5% 4.2% 1.6%
Op.Income 137.70
144.00
134.50
149.80
153.10
growth rate 4.6% -6.6% 11.4% 2.2%
IBT 71.30
104.30
-353.70
114.30
-122.70
growth rate 46.3% -100.0% 100.0% -100.0%
Net Income 50.50
98.60
-272.60
93.90
-123.50
growth rate 95.3% -100.0% 100.0% -100.0%
EPS
growth rate
Gross Profit 502.50
516.90
499.20
525.20
533.90
growth rate 2.9% -3.4% 5.2% 1.7%
R&D 52.70
53.20
57.30
61.40
60.40
growth rate 1.0% 7.7% 7.2% -1.6%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (0.00)

YOY Growth Grade:

F (15.11)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

Current EPS is negative, therefore value price cannot be calculated.

PE and EPS

Historical Current Forward
PE 10.28 -351.07 16.54
EPS / Growth 9.3% -0.15 9.9%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 1.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.0% 6.7% 6.7%
Future PE 2.00 13.42 13.42
Future EPS 0.00 0.00 0.00
Value Price
MOS %
0.00
-100.0%
0.00
-100.0%
0.00
-100.0%
MOS Price 0.00 0.00 0.00
IRT 99.00 99.00 99.00

Graham Number:

Current EPS is negative, therefore Graham Number cannot be calculated.
NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.